Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared ...

Bionano specializes in OGM using its Saphyr analysis system. In genome analysis, OGM allows researchers to find large structural variations. This is an important step in testing for genetic diseases.

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better ...

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due ...

Bionano Genomics (BNGO) didn't quite "beat earnings" when it reported its Q1 2021 results on Thursday last week -- and that's okay. Bionano posted a $9.9 million net loss for the quarter, somewhat ...

Bionano expects to raise roughly $200 million via the sale of 33,333,350 shares of common stock at a price of $6 per share. It also gave underwriters the option to purchase (and subsequently sell) an ...

Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, ...

Bionano Genomics, Inc. BNGO, CorMedix Inc. CRMD and Eloxx Pharmaceuticals, Inc. ELOX are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported first-quarter revenues of $3 ...

Shares of Bionano Genomics Inc. gained 10.3% in premarket trading on Friday following a week of heavy trading on the stock. The company's stock price has tripled since the start of the year, closing ...